PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Webcasts|October 30, 2019
Choosing The Right CDMO For Late-Phase Clinical Trials
Author(s)Thermo Fisher Scientific
For many pharmaceutical companies that do not have their own facilities, choosing the right partner for late-phase clinical trials and commercial production is a critical aspect in the management of parenteral products. Join Christy Eatmon, Global SME, Sterile Drug Products at Thermo Fisher Scientific, where she will lead a webcast that will offer insight into the importance of looking for a partner with extensive experience in the parenteral arena. Live: Wednesday, Oct. 30, 2019 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET On demand available after final airing Oct. 30, 2020 Register free
Register free:
Event Overview:
For many pharmaceutical companies that do not have their own facilities, choosing the right partner for late-phase clinical trials and commercial production is a critical aspect in the management of parenteral products. Oftentimes, small contract development and manufacturing organizations (CDMOs) can provide early-phase clinical material but do not have the ability to move through late stage and into commercialization.
This webcast will offer an insight into the importance of looking for a partner with extensive experience in the parenteral arena, as products move through clinical phases and toward commercialization. Learn how the right partner should be able to manage programs at all clinical stages, as well as have the ability and expertise in moving compounds from early-to late-clinical stage and through the process validation process to commercial launch. The webinar also features a case study that highlights the pathway to commercialization.
Key Learning Objectives:
- Defining Phase 3
- Cost and Scale of Phase 3 Work
- Criteria to Consider When Evaluating a CDMO
Speaker: Christy Eatmon, Global SME, Sterile Drug Products, Thermo Fisher Scientific
Time and Date: Wednesday, Oct. 30, 2019 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET
On demand available after final airing Oct. 3, 2020
Sponsor: Thermo Fisher Scientific
Register free:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.